ArticleGland surgery2025
Developing and validating a nomogram to forecast clinically relevant postoperative pancreatic fistula following distal pancreatectomy.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: After distal pancreatectomy (DP), clinically relevant postoperative pancreatic fistula (CR-POPF) is a critical complication that adversely affects the prognosis of patients. The present study identified the risk factors for CR-POPF occurrences, as well as developing a nomogram to predict their risk after DP. Methods: We retrospectively examined 300 medical records, obtaining the patients' preoperative clinical baseline data, laboratory indicators, preoperative computed tomography (CT) data, and intraoperative clinical information. We determined CR-POPF independent risk factors using univariate as well as multivariate logistic regression analyses. We created a risk nomogram based on these variables and used the bootstrap method for internal validation. Area under the curve (AUC) assessed the nomogram's predictive power. The nomogram's clinical value and viability were evaluated using decision curve analysis (DCA) as well as clinical impact curve (CIC). Results: CR-POPF developed in 84 of the 300 patients (28.0% incidence). CR-POPF was found to be independently risked by operation time (P=0.002), preoperative C-reactive protein (CRP) levels (P<0.001), CT (pancreas)-to-CT (psoas major) ratio (P<0.001), and pancreatic thickness (PT) at transection site (P<0.001). The nomogram's AUC was 0.901, which, along with the DCA, highlighted the nomogram's excellent performance, surpassing those of four alternative CR-POPF prediction models. The nomogram has an immense net clinical advantage, according to the CIC. Conclusions: The developed nomogram can be useful in identifying high-risk patients and formulating individualized perioperative plans to prevent the risk of CR-POPF formation in patients undergoing DP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.